Loading...
•
Sep 30
Editas Q3 2025 Earnings Report
Editas reported Q3 2025 results with narrowed net loss, lower R&D and G&A expenses, and increased collaboration revenue.
Key Takeaways
Editas significantly reduced its net loss in Q3 2025 compared to the prior year, supported by higher collaboration revenue and reduced R&D expenses following program discontinuation.
Net loss narrowed to $25.1M from $62.1M in Q3 2024.
Revenue rose sharply to $7.5M due to BMS milestone recognition.
R&D expenses dropped significantly after reni-cel discontinuation.
Cash runway extended into Q3 2027 with $165.6M on hand plus ATM proceeds.
Editas
Editas
Editas Revenue by Segment
Revenue by Segment
Collab. & R&D Revenue
CapyFin.com Forward Guidance
Editas aims to submit IND/CTA for EDIT-401 by mid-2026, with initial human proof-of-concept data expected by year-end 2026. The cash position supports operations through Q3 2027.
Positive Outlook
- IND/CTA for EDIT-401 targeted for mid-2026.
- Initial human proof-of-concept data expected by end of 2026.
- ≥90% LDL-C reduction in preclinical NHP and mouse models.
- Durability of effect demonstrated in three-month mouse study.
- Cash runway extended into Q3 2027.
Challenges Ahead
- No current revenue from product sales.
- Ongoing operating losses continue despite reduced expenses.
- Cash balance decreased from $269.9M to $165.6M year-to-date.
- Increased reliance on ATM facility for funding.
- Clinical progress dependent on regulatory milestones in 2026.